Stay updated on Pembrolizumab in HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HCC Clinical Trial page.

Latest updates to the Pembrolizumab in HCC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe record for a Phase 2 pembrolizumab study in advanced hepatocellular carcinoma is displayed, including its eligibility criteria, study design, outcome measures, results, and study documents.SummaryDifference42%

- Check15 days agoChange DetectedThe displayed site revision changed from v3.7.2 to v3.8.0 while the study page continued to show a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA sitewide NIH notice announces a transition-related update to terminology, including the use of “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1 while the page continued to show a 403 error.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now shows a 403 Forbidden error screen with minimal navigation, replacing the previous study details for the NCT03163992 trial; the content sections and links related to the trial have been removed or hidden.SummaryDifference17%

Stay in the know with updates to Pembrolizumab in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HCC Clinical Trial page.